Abstract: Objective The aim of this study was to observe the very short-term efficacy of concentrated ascites reinfusion (CAR) and terlipressin combination therapy in the treatment of patients with liver cirrhosis (LC) and refractory ascites (RA). Methods 62 patients with LC and RA were admitted to our hospital between May 2016 and May 2021, and were randomly divided into control (n=31) and observation group (n=31). The patients in the control group were treated with CAR, and those in the observation group were treated with CAR and terlipressin combination. The regimen lasted for 7 days in the two groups. The blood urea nitrogen (BUN) and serum creatinine (sCr) levels were detected by an automatic biochemical analyzer. The diameter of portal vein (DPV), the diameter of splenic vein (DSV), the velocity of portal vein (VPV) and the velocity of splenic vein (VSV) were measured with ultrasonography. The WHO quality of life (WHOQOL-BREF) questionnaire was applied to evaluate the quality of life (QOL). The abdominal circumference, depth of ascites, 24 hour urine volume and the incidence of adverse reactions were recorded. Results At the end of 7 day treatment, the abdominal circumference was (85.5±4.5)cm, and the depth of ascites was (35.2±3.4)mm, both significantly smaller than [(88.4±4.3)cm and (47.2±5.1)mm, respectively, P<0.05], while the 24 hour urine volume was (1530.8±30.2)ml, significantly greater than [(1248.6±28.4)ml, P<0.05] in the control; the BUN and sCr levels were (6.6±1.5)μmol/L and(104.2±8.7)μmol/L, both significantly lower than [(9.8±2.4)μmol/L and (133.5±11.2)μmol/L, respectively, P<0.05] in the control, while there was no significant difference respect to liver function tests in the two groups (P>0.05); the VPV was (25.7±5.4)cm/s, significantly higher than [(22.5±4.6)cm/s, P<0.05] in the control, while there were no significant differences respect to DPV, DSV and VSV in the two groups(P>0.05); the total WHOQOL-BREF score was (65.6±12.3), significantly higher than [(56.1±9.8), P<0.05] in the control. Conclusion The CAR and terlipressin combination therapy in the treatment of patients with LC and complicated RA is relatively efficacious, from the point of view of the very short-time, which could improve kidney functions and promote ascites subsided, thereby improve the quality of life.

Key words: Liver cirrhosis, Refractory ascites, Concentrated ascites reinfusion, Terlipressin, Therapy